Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Mon... (d the inability to continue operations a...)

Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results

Date:8/11/2009

d the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2008, "Risk Factors" in Vion's Post-Effective Amendments on Form S-1 Registration Statement filed on March 23, 2009 and under Item 1A, "Risk Factors" in Vion's Form 10-Q for the quarter ended March 31, 2009. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    COMPANY CONTACT:  Vion Pharmaceuticals, Inc.
                      Alan Kessman, Chief Executive Officer
                      Howard B. Johnson, President & CFO
                      (203) 498-4210

VION PHARMACEUTICALS, INC.
(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended Six Months Ended
June 30, June 30,
(In thousands, except per share data) 2009 2008 2009 2008
-------------------------------------------------------------------------
(Unaudited) (Unaudited)

Technology license fee revenue $5 $13 $10 $27

Operating expenses:
Clinical trials 1,590 2,953 2,611 5,807
Other research and development 1,536
'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved
0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:

(Date:5/19/2013)... IL (PRWEB) May 19, 2013 In partnership ... LLC, E-dentist.com has announced the launch of an SEO website ... dentists get high rankings in Google. , http://www.e-dentists.com/ ... not pay for the service until they see results. Dentists ... The lead generation websites run by JD Media Surge, LLC ...

(Date:5/19/2013)... (PRWEB) May 19, 2013 Grinding your ... just losing sleep, or annoying your spouse. At the ... by CNY Central (“Snoring and Teeth Grinding Could Be ... of teeth grinding can be hard to prevent. Apparently, ... Americans, and one of its symptoms is a habit ...

(Date:5/19/2013)... The report “Feed Additives Market by Types, Livestock ... 2017” published by MarketsandMarkets, defines and segments the global ... the global volume and revenue for the animal feed ... for the global market with analysis of trends, opportunities, ... segmented and revenue is forecasted on the basis of ...

(Date:5/19/2013)... May 19, 2013 Farming methods have ... in the ground 10,000 years ago. Most recently, the ... productivity by using genetically engineered seeds and by applying ... a backlash to these techniques due to the adverse ... and a corresponding surge in interest in organic, sustainable ...

(Date:5/19/2013)... Yeast infections are common in both men and women. ... human body. A new yeast infection treatment product has been ... method of application to help eliminate over growth of the ... men and women searching for a natural process of yeast ... food and is stored in the intestines. In small consumable ...

Breaking Medicine News(10 mins):Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2 Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2 Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3 Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2 Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3 Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2 Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3 Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2

[0] Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC [0] Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder [0] Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets [0] Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics [0] A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount

... ... enrollment grew by 708,000 members during 2007, - Selling, general and administrative expense ratio continued to improve, ... Operating cash flow exceeded $4.3 billion for the year, or 1.3 times net ... income, - Company reiterates diluted earnings per share target of $6.41 for ...

... Mentally Fit Years Longer, KIRKLAND, Wash., Jan. 23 ... people need long term care today," says Cameron,Truesdell, CEO ... care insurance agency. "That shouldn,t be, so we,re going ... To that end, the,company is offering a free guidebook ...

... Approval for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), is ... the Prevention ... Birth in Singleton Pregnancies, ST. LOUIS, Jan. 22 ... pharmaceutical company that,develops, manufactures, acquires and markets technology-differentiated,branded and ...

... Group of Lawmakers Vow to Fight Premature Birth in Ohio, ... and Ohio,s rate of premature birth is up once again ... 19,321 preterm births were recorded for,2005 and over 20 lawmakers ... of Ohio,s babies. "We were happy to receive the news ...

... cleaners with the hospital laundry, FORT WORTH, Texas, Jan. ... Huguley Memorial Medical Center after,the hospital staff sent their newborn ... July 8, 2007, Kourtney McGee gave birth to her son, ... was taken to the,hospital morgue., As Ms. McGee and ...

... Sargent of Success Design International, to offer a new course in ... ... The business of,life coaching takes another step forward with the Hemispheric,Integration(TM) ... science of personal achievement. It is an art,because the way each person ...

WellPoint Reports Fourth Quarter and Full Year 2007 Results Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM)Ohio Prematurity Caucus Forming to Meet Challenge A Fort Worth Couple Sues Huguley Memorial Medical Center Spencer Institute Offers a Home-Training Course for Hemispheric Integration & Neuro-linguistics Coach Certification

(Date:5/16/2013)... N.C. , May 16, 2013 Today, the ... North Carolina House of Representatives recently approved ... for chemotherapy from charging patients higher out-of-pocket fees for ... formularies, many of which have more severe side-effects. However, ... limit of $300, which will continue to be a ...

(Date:5/16/2013)... -- Alere Inc. (NYSE: ALR ), a global leader ... home through the merger of rapid diagnostics and health management, ... its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). The ... record of Series B stock at the close of business ... the amount of all dividends accrued from April 1, 2013 ...

(Date:5/16/2013)... Calif. , May 16, 2013 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies for ... Richard King , President and CEO, will ... at the Sheraton New York Hotel in New ... May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT. ...

Breaking Medicine Technology:National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2 National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3 AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2 AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3

[0] National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill [0] Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock [0] AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference

... genomics, SAN DIEGO, April 14 Systems ... Inc. (CTI) (Nasdaq,and MTAX: CTIC), presented data from ... more likely to respond to treatment with the,experimental ... Research (AACR) annual meeting. These findings will be ...

... During Wednesday,s Satellite Symposium,3: The Challenges of ... the,International Society of Heart and Lung Transplantation ... researchers discussed some of,the unique challenges in ... CF., A highlight of the session ...

Cached Medicine Technology:New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 2 New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 3 New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 4 New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 5 Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2 Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3

New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting

GP8R is a powerful 3-liter large capacity centrifuge which is flexible and easy to use with refrigeration facility. Performs separations 50-100% faster than the rest, powerful, accommodating and conv...

... Rotanta 460 family of ... line that meets a ... They feature high capacity, ... state-of-the-art technology and high ...

... 15 centrifuge provides all the ... for today's full-service clinical lab ... a speed up to 15,300 ... spin tubes, plates and rotors ...

BD Dynac III is a general purpose centrifuge. Digitally precise variable speeds, microprocessor controlled, versatile rotor choices, user programmable: speed, RCF and time, 10 program (memory) settin...

Medicine Products:

Centra-GP8R Rotanta 460R Spinchron 15 Refrigerated Centrifuge Dynac III